|Articles|November 1, 2003
COMPARING CREAMS
Investigators with Dermatology Associates, St. Luke's-Roosevelt Hospital, N.Y., conducted two 8-week, multi-center, randomized, investigator-blind studies to compare the efficacy and safety of a hydrophilic cream formulation containing tretinoin 0.05 percent, hydroquinne 4.0 percent and fluocinolone acetonide 0.01 percent (RA+HQ+FA) with the dual-combination agents tretinoin hydroquinone, tretinoin plus fluocinolone acetonide, and hydroquinone plus fluocinolone acetonide.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Top 5 Articles of the Week: November 30-December 5
3
The Weekly Roundup: December 1-5
4
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
5















